RRML - The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- February 2020 -
 
The role of neutrophil to lymp... 22
The direct deleterious effect ... 20
The usefulness of neutrophil/l... 19
Quality Control Strategy for A... 16
Genetic testing in pediatrics ... 11
Variability of ex-vivo stimula... 10
A rare case of acute myeloid l... 10
Is there a correlation between... 9
Relationships between serum pr... 8
HBV genotypes circulation in p... 8

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 21(3)/2013 DOI:10.2478/rrlm-2013-0033
XML
TXT

The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis

Aurelia Tatic, Cerasela Jardan, Otilia Georgescu, Oana Stanca, Madalina Vasilica, Sorina Badelita, Ana Manuela Crisan, Adriana Colita, Dan Colita, Genica Vulcan, Anca Roxana Lupu, Ionel Iosif, Daniel Coriu


Abstract:

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal stem cell disorders characterized by ineffective hematopoiesis with dysplastic changes in one or more myeloid cell lines and increased risk of progression to acute leukemia. The current diagnosis criteria include the morphology of peripheral blood (PB) and bone marrow (BM), bone marrow biopsy and cytogenetic exam. Material and method. For this study, we have analyzed 33 patients diagnosed with lower-risk MDS (IPSS 0 and intermediate-1) according to the World Health Organization (WHO) classification (2001) between 2008 and 2012. The diagnosis was confirmed by blood cell counts, bone marrow (aspirate and biopsy) exam and cytogenetic exam. Other causes of cytopenia or dysplastic changes were excluded. Results. The types of MDS according to the WHO classification were: nine patients with refractory anemia (RA) (27.27%), sixteen patients with refractory anemia with ringed sideroblasts (RARS) (48.48%), and eight patients with refractory cytopenia with multilineage dysplasia (RCMD) (24.24%) out of which two with refractory cytopenia with multilineage dysplasia with ringed sideroblasts (RCMD-RS). Cytogenetic exam was performed in all patients, but analyzable metaphases for cytogenetic exam were obtained only from twenty five patients. The patients who did not have analyzable metaphases on cytogenetic exam were considered low risk if: they had only one cytopenia and the percent of bone marrow blasts was less than 5%. For all patients who had analyzable metaphases at cytogenetic exam, the International Prognostic Scoring System (IPSS) and Revised International Prognostic Scoring System (R-IPSS) scores were determined, and their survival and the death leading events were observed. According to IPPS (1997), the cytogenetic exam was good in 17 cases, intermediate in 1 case and poor in 7 cases. The IPSS score was low in 13 cases and intermediate-1 in 12 cases. According to R-IPSS, cytogenetic exams had been very good and good in 17 cases, intermediate in 1 case, poor in 6 cases and very poor in 1 case. R-IPSS was very low and low in 17 cases and intermediate and high in 8 cases. Conclusions. This new R-IPSS score at diagnosis allows a more accurate classification of patients into risk groups and thus enables risk adapted therapy.

Keywords: myelodisplastic syndromes,International Prognostic Scoring System (IPSS),Revised International Prognostic Scoring System (R-IPSS)

 
  PDF Download full text PDF
(149 KB)
     
 
How to cite
Tatic A, Jardan C, Georgescu O, Stanca O, Vasilica M, Badelita S, et al. The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis. Rev Romana Med Lab. 2013;21(3):343-51. DOI:10.2478/rrlm-2013-0033